Buscar
Mostrando ítems 11-20 de 151
Resultados del tratamiento con peginterferón alfa-2a y ribavirina en pacientes con hepatitis crónica C
(2011)
Background: The current treatment recommendation for chronic hepatitis C
virus infection is the combination of peginterferon and ribavirin for 24 or 48 weeks,
depending on the viral genotype. The aim of the therapy is ...
Low- and standard-dose peginterferon alfa-2a for chronic hepatitis c, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response
(WILEY-BLACKWELL PUBLISHING, INC, 2010)
Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
(Brazilian Society of Infectious Diseases, 2006-02-01)
Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous ...
Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
(The Brazilian Journal of Infectious Diseases and Contexto Publishing, 2006-02)
Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous ...
Retreatment of hepatitis C patients who previously experienced treatment failure
(ContextoSalvadorBrasil, 2007)
Hepatitis B virus surface antigen seroconversion in HIV-infected individual after pegylated interferon-alpha treatment: a case report
(Biomed Central LtdLondonInglaterra, 2013)
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
(Brazilian Society of Infectious Diseases, 2014)